# US 11,298,406 B1 · Treatment of connective tissue injuries

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,298,406 B1
- Document ID: US11298406B1
- Status: Granted
- Kind: B1
- Application number: 17/472,366
- Filed: 2021-09-10
- Granted: 2022-04-12
- Earliest claimed: 2021-09-10
- Assignees: Bjorn Eek
- Applicants: Bjorn Eek
- Inventors: Bjorn Eek
- Web page: https://patentgrep.com/patent/US11298406B1

## CPC

- A61K 38/1841: {Transforming growth factor [TGF]}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/7008: Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
- A61K 31/728: Hyaluronic acid
- A61K 31/737: Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate (A61K31/727 takes precedence)
- A61K 38/18: Growth factors; Growth regulators
- A61K 47/02: Inorganic compounds
- A61K 47/18: Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/36: Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This disclosure relates to treating a connective tissue injury. The treatment involves injecting, or otherwise administering, a therapeutic composition into an animal, such as a human being, in need thereof. The therapeutic composition may contain transforming growth factor beta 1 (TGF-β1) and/or transforming growth factor β 2 (TGF-β2), connective tissue growth factor (CTGF), and a pharmaceutically acceptable excipient or a secondary agent.

## Claims

### Claim 1

A method of treating a connective tissue injury, comprising injecting a therapeutic composition within 6 inches of a fibro-periosteal junction of an injured connective tissue in an animal in need thereof, wherein the therapeutic composition comprises transforming growth factor beta 1 (TGF-β1), connective tissue growth factor (CTGF), and a pharmaceutically acceptable excipient or a secondary agent, wherein the connective tissue injury is a result of an automobile collision, a sports injury, or other trauma.

### Claim 2 (depends on 1)

The method of claim 1, wherein the animal is a human being.

### Claim 3 (depends on 1)

The method of claim 1, wherein the therapeutic composition is injected within 6 inches of a fibro-periosteal junction of a tendon of the animal.

### Claim 4 (depends on 1)

The method of claim 1, wherein the therapeutic composition is injected within 6 inches of a fibro-periosteal junction of a fascia of the animal.

### Claim 5 (depends on 1)

The method of claim 1, wherein the therapeutic composition is injected within 6 inches of a fibro-periosteal junction of a ligament of the animal.

### Claim 6 (depends on 1)

The method of claim 1, wherein the therapeutic composition is injected within 6 inches of a fibro-periosteal junction of a joint capsule of the animal.

### Claim 7 (depends on 1)

The method of claim 1, wherein the pharmaceutically acceptable excipient or the secondary agent comprises glucosamine.

### Claim 8 (depends on 1)

The method of claim 1, wherein the pharmaceutically acceptable excipient or the secondary agent comprises chondroitin.

### Claim 9 (depends on 1)

The method of claim 1, wherein the pharmaceutically acceptable excipient or the secondary agent comprises dextrose.

### Claim 10 (depends on 1)

The method of claim 1, wherein the pharmaceutically acceptable excipient or the secondary agent comprises a local anesthetic.

### Claim 11 (depends on 1)

The method of claim 1, wherein the pharmaceutically acceptable excipient or the secondary agent comprises carboxymethyl cellulose.

### Claim 12 (depends on 1)

The method of claim 1, wherein the pharmaceutically acceptable excipient or the secondary agent comprises hyaluronic acid.

### Claim 13 (depends on 1)

The method of claim 1, wherein the pharmaceutically acceptable excipient or the secondary agent comprises a phosphate buffer saline.